FCGR1A and acute myeloid leukemia: We observed that the expression of CD64 on AML cells from patients inhibited the ADCC induced by antibodies targeting CD123 in vitro and ex vivo, but had no effect on CD123-NKCE, which displayed potent antitumor activity against primary malignant AML blasts and cell lines regardless of CD64 expression.